Geneseq Biosciences is a biotechnology company based in Melbourne, Australia, dedicated to advancing the early and accurate diagnosis of cancer.
Guided by a deep understanding of cancer biology, Geneseq’s R&D pipeline combines our international expertise in in-vitro diagnostic (IVD) assay design, with scalable bioinformatics and knowledge of regulatory requirements.
Melaseq™ is our first clinically-validated, NATA-accredited genomic test. It harnesses the latest insights in melanoma biology, to provide clinicians with a powerful new tool for detecting and diagnosing the deadliest form of skin cancer.
